Today's Research Reports on Stocks to Watch: Pain Therapeutics and Ionis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / October 25, 2017 / Pain Therapeutics saw its shares explode in Tuesday trading after positive results were revealed from the Phase 1 study of its PTI-125 drug to treat Alzheimer's. Shares of Ionis, on the other hand, weren't so lucky and tumbled after its commercialization partner Biogen reported weaker than expected sales in the U.S. of Spinraza. Both companies are collaborating on Spinraza, which treats spinal muscular atrophy.
RDI Initiates Coverage on:
Pain Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=PTIE
Ionis Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=IONS
Pain Therapeutics, Inc. shares skyrocketed on Tuesday following news that the company had successful phase 1 clinical study results of PTI-125. Shares closed up 27.27% yesterday on a little over 19 million shares traded and even saw gains as high as almost 60% during intra-day trading. The company's investigational Alzheimer's drug PTI-125, showed that it was safe and well tolerated in healthy volunteers. This has set the motion for a Phase 2 Trial in adults who have Alzheimer's Disease. CEO Remi Barbier commented, "The clinical data are encouraging [...] Given the absence of dose-limiting effects in healthy adults, an excellent non-clinical safety database, a strong scientific rationale, and multiple peer-reviewed publications and research grant awards, we are eager to move this drug program to the next level of development." Barbier has also said, "Finding a way to diagnose disease at an early-stage is vitally important. A blood test may help detect Alzheimer's disease before symptoms occur, or rule out other possible causes of memory problems, or might be used as a biomarker to measure the efficacy of drug candidates during clinical trials."
Access RDI's Pain Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PTIE
Ionis Pharmaceuticals, Inc. shares saw red on Tuesday, closing the day down 12.40% on about 6.2 million shares traded. The pharma company's stock started dropping after its commercialization partner Biogen reported its third-quarter financial report and revealed that sales of its drug Spinraza, did not meet forecasts. Both Ionis and Biogen are working together on Spinraza which treats spinal muscular atrophy (SMA). The treatment was the first of its kind to be FDA approved last December. Many had expected the drug to be a multi-billion dollar drug given the list price of $750,000 in year 1 post which the price drops to $375,000 per year. The drug had been doing fine this year with $47 million in Q1, $203 million in Q2, and $271 million in Q3. So why are traders this disappointed? Because U.S. sales of the drug were $197.6 million when the forecast was $242 million.
Access RDI's Ionis Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IONS
Our Actionable Research on Pain Therapeutics, Inc. (NASDAQ: PTIE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
